Norway Vaccine Market Size & Outlook, 2026-2033
- Pharmaceuticals
- Vaccines
- Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the vaccine market
Norway vaccine market highlights
- The Norway vaccine market generated a revenue of USD 515.9 million in 2025 and is expected to reach USD 787.2 million by 2033.
- The Norway market is expected to grow at a CAGR of 5.2% from 2026 to 2033.
- In terms of segment, viral vaccines was the largest revenue generating indication in 2025.
- Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.
Vaccine market data book summary
| Market revenue in 2025 | USD 515.9 million |
| Market revenue in 2033 | USD 787.2 million |
| Growth rate | 5.2% (CAGR from 2026 to 2033) |
| Largest segment | Viral vaccines |
| Fastest growing segment | Other Indication |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Viral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication |
| Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
Other key industry trends
- In terms of revenue, Norway accounted for 0.7% of the global vaccine market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany vaccine market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 3,784.9 million by 2033.
In Norway, the public healthcare system and private health insurance are available. Most of the population of the country is covered by the public health insurance system. The quality of insurance service when it comes to private versus public is the same.
The healthcare system in Norway follows the principles of free choice of providers and universal access decentralization. It is financed by co-payments, taxation, and income related to employee & employer contributions. All citizens of Norway are covered under the national insurance scheme supervised by the Norwegian Health Economics Administration and private medical insurance companies.
The National Insurance Scheme (NIS) covers expenses for medical supplies and medicines prescribed for outpatient use. The coverage is limited to the treatment of severe illnesses or risk factors that may cause or aggravate serious illnesses. Co-pay of up to USD 246 may also be required for blue prescriptions.
No credit card required*
Publish Date: Jul 28, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Vaccine Market Scope
Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | www.seruminstitute.com/ |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| BioNTech SE ADR | View profile | 6,133 | An der Goldgrube 12, Mainz, RP, Germany, D-55131 | www.biontech.de |
| Moderna Inc | View profile | 5,600 | 200 Technology Square, Cambridge, MA, United States, 02139 | www.modernatx.com |
Norway Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Vaccine Market Outlook will help companies and investors design strategic landscapes.
Viral Vaccines was the largest segment with a revenue share of 64.45% in 2025.
Horizon Databook has segmented the Norway vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.
In Norway, the public healthcare system and private health insurance are available. Most of the population of the country is covered by the public health insurance system. The quality of insurance service when it comes to private versus public is the same.
The healthcare system in Norway follows the principles of free choice of providers and universal access decentralization. It is financed by co-payments, taxation, and income related to employee & employer contributions. All citizens of Norway are covered under the national insurance scheme supervised by the Norwegian Health Economics Administration and private medical insurance companies.
The National Insurance Scheme (NIS) covers expenses for medical supplies and medicines prescribed for outpatient use. The coverage is limited to the treatment of severe illnesses or risk factors that may cause or aggravate serious illnesses. Co-pay of up to USD 246 may also be required for blue prescriptions.
- Norway Vaccine Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Viral Vaccines
- Bacterial Vaccines
- Cancer Vaccines
- Allergy Vaccines
- Other Indication
- Norway Vaccine Market Type Outlook (Revenue, USD Million , 2021-2033)
- Subunit Vaccines
- Inactivated
- Live Attenuated
- mRNA Vaccines
- Viral Vector Vaccines
- Norway Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Parenteral
- Nasal
- Norway Vaccine Market Age Group Outlook (Revenue, USD Million , 2021-2033)
- Pediatric Age Group
- Adult Age Group
- Norway Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital & Retail Pharmacies
- Government Suppliers
- Others Distribution Channel
Reasons to subscribe to Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Vaccine Market Outlook databook
- Our clientele includes a mix of Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway Vaccine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Norway Vaccine Market, 2021-2033 (US$M)
Norway vaccine market statistics, by indication, 2021-2033 (US$M)
